A couple of months ago, I read an SA article about Harvard Bioscience (NASDAQ:HBIO) that posited there would be a significant upside move in price related to its spin-off of Harvard Apparatus Regenerative Technology (HART). The basis for the bullish thesis rested on the expectation that the market would respond enthusiastically to a new solo player in regenerative medicine. The author's view seemed reasonable in light of the bullish reception Organovo (NYSEMKT:ONVO) received when it up-listed on July 9.
I was already aware of HART because it was on deck to price its shares for an IPO back in the spring, but pulled back. It formally withdrew its S-1 on May 1, deciding instead to pursue...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|